Timedora
Free Practice Quiz Question List

3 Direct Oral Anticoagulants Online Quiz Questions

Use this free practice quiz with 20 questions to review 3 Direct Oral Anticoagulants, test your knowledge, and prepare for your next test or exam.

20 questions
01
True or false
1 point

INR is used to guide warfarin therapy, not to measure or adjust the effect of a direct oral anticoagulant. True or false?

  1. A

    True

  2. B

    False

02
Fill in the blank
1 point

The specific reversal agent for dabigatran is .

03
Choose one
1 point

For acute DVT or PE treatment, which pair of DOACs is started after an initial course of parenteral anticoagulation?

  1. A

    Apixaban and rivaroxaban

  2. B

    Dabigatran and edoxaban

  3. C

    Apixaban and edoxaban

  4. D

    Rivaroxaban and dabigatran

04
Written response
1 point

In what month and year did the manufacturer end U.S. commercial sales of andexanet alfa? Enter the month and year in YYYY-MM format.

05
Fill in the blank
1 point

Complete the statements: Dabigatran directly inhibits . Apixaban, rivaroxaban, and edoxaban directly inhibit .

06
Written response
1 point

Which organ function is especially important to assess because impaired clearance can increase DOAC exposure?

07
Choose all
1 point

Select all accurate statements about strong drug inducers and DOACs.

  1. A

    Rifampin and carbamazepine can reduce exposure to some DOACs and potentially weaken anticoagulation.

  2. B

    Rifampin and carbamazepine reliably increase apixaban exposure and therefore require a lower dose.

  3. C

    Strong combined P-gp and CYP3A4 inducers such as rifampin and carbamazepine should generally be avoided with apixaban or rivaroxaban.

  4. D

    Strong inducers should generally be combined with apixaban to prevent bleeding.

08
True or false
1 point

A normal PT/INR or aPTT result always rules out a clinically relevant DOAC level. True or false?

  1. A

    True

  2. B

    False

09
Choose one
1 point

For severe bleeding involving a factor Xa inhibitor in the U.S. situation described, which statement best reflects the recommended approach?

  1. A

    Use idarucizumab as the specific antidote for apixaban and rivaroxaban.

  2. B

    Use andexanet alfa, which remains available for U.S. commercial sale.

  3. C

    Follow local emergency protocols; four-factor prothrombin complex concentrate may be considered, but it is not a specific antidote.

  4. D

    Adjust the dose to reach a target INR.

10
Choose all
1 point

Select all uses of DOACs described in the material.

  1. A

    Preventing stroke in nonvalvular atrial fibrillation

  2. B

    Treating DVT or PE and preventing recurrence

  3. C

    Treating bacterial infections

  4. D

    Preventing clots after certain orthopedic surgeries

11
Open ended
1 point

What key safety advice should a clinician give a patient taking a DOAC about taking the medicine, warning signs, other medicines, and upcoming procedures?

12
Choose one
1 point

Which statement best explains why one DOAC should not be substituted for another milligram for milligram?

  1. A

    All DOACs have identical approved uses and can be substituted milligram for milligram.

  2. B

    Indications and dosing are drug-specific, so DOACs are not interchangeable milligram for milligram.

  3. C

    The same dose of any DOAC produces the same effect in every patient.

  4. D

    Only the drug name differs; dosing and use are otherwise uniform.

13
Written response
1 point

In the context of clot treatment, what does DVT stand for?

14
True or false
1 point

A patient taking a DOAC feels better and plans to stop the medicine without consulting the prescriber. Is this a safe plan?

  1. A

    True

  2. B

    False

15
Choose one
1 point

A patient’s DOAC is being changed to a different DOAC. Which approach is appropriate when selecting the new dose?

  1. A

    Replace the current DOAC with the same milligram dose of another DOAC.

  2. B

    Check the new drug’s specific indication and dosing rather than substituting milligram for milligram.

  3. C

    Use the same dose only if both drugs are taken once daily.

  4. D

    Choose the replacement dose by targeting the patient’s INR.

16
Written response
1 point

A patient taking a DOAC asks which unusual stool appearance should be reported promptly as a possible warning sign. Enter the stool appearance.

17
Choose one
1 point

A patient taking a DOAC asks whether they can start over-the-counter ibuprofen for pain. What is the safest advice?

  1. A

    Start ibuprofen, but take it several hours apart from the DOAC.

  2. B

    Use aspirin instead of the DOAC on days when pain is worse.

  3. C

    Do not start ibuprofen unless the prescriber approves it.

  4. D

    Take naproxen routinely because it does not affect bleeding risk.

18
Choose one
1 point

A patient with impaired kidney function is being assessed for DOAC treatment. Which statement should guide the medication review?

  1. A

    Review kidney function carefully, particularly if the patient is taking dabigatran.

  2. B

    Use the INR to determine whether kidney function is adequate for any DOAC.

  3. C

    Kidney function is not relevant because DOACs are cleared only by the liver.

  4. D

    Assess kidney function only when a patient takes apixaban.

19
Choose one
1 point

A patient taking a DOAC asks whether the dose should be changed to reach a target INR. Which response is appropriate?

  1. A

    Increase the DOAC dose until the INR reaches the warfarin target.

  2. B

    Use the INR to confirm that the DOAC has reached its full effect.

  3. C

    Reduce the DOAC dose whenever the INR is within the warfarin target range.

  4. D

    Do not adjust the DOAC to reach a target INR; INR guides warfarin therapy.

20
Choose one
1 point

A patient is starting treatment for a new DVT. Which statement about the initial treatment plan is accurate?

  1. A

    All four drugs require an initial course of parenteral anticoagulation.

  2. B

    Dabigatran and edoxaban require an initial parenteral course, while apixaban and rivaroxaban have oral regimens that can begin without it.

  3. C

    Only apixaban and rivaroxaban require an initial parenteral course.

  4. D

    None of the four drugs can be used to treat acute DVT without an initial parenteral course.